Pharsight

Eucrisa patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8039451 ANACOR PHARMS INC Boron-containing small molecules
Jun, 2029

(5 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8501712 ANACOR PHARMS INC Boron-containing small molecules as anti-inflammatory agents
Feb, 2027

(2 years from now)

US9682092 ANACOR PHARMS INC Boron-containing small molecules as anti-inflammatory agents
Feb, 2027

(2 years from now)

US9682092

(Pediatric)

ANACOR PHARMS INC Boron-containing small molecules as anti-inflammatory agents
Aug, 2027

(3 years from now)

US8501712

(Pediatric)

ANACOR PHARMS INC Boron-containing small molecules as anti-inflammatory agents
Aug, 2027

(3 years from now)

US8039451

(Pediatric)

ANACOR PHARMS INC Boron-containing small molecules
Dec, 2029

(5 years from now)

US8168614 ANACOR PHARMS INC Boron-containing small molecules as anti-inflammatory agents
Jan, 2030

(5 years from now)

US8168614

(Pediatric)

ANACOR PHARMS INC Boron-containing small molecules as anti-inflammatory agents
Jul, 2030

(6 years from now)

Eucrisa is owned by Anacor Pharms Inc.

Eucrisa contains Crisaborole.

Eucrisa has a total of 8 drug patents out of which 0 drug patents have expired.

Eucrisa was authorised for market use on 14 December, 2016.

Eucrisa is available in ointment;topical dosage forms.

Eucrisa can be used as method of treating mild to moderate atopic dermatitis..

Drug patent challenges can be filed against Eucrisa from 23 September, 2022.

The generics of Eucrisa are possible to be released after 20 July, 2030.

Drug Exclusivity Drug Exclusivity Expiration
New Dosing Schedule(D-191) Apr 03, 2026
New Chemical Entity Exclusivity(NCE) Dec 14, 2021
Pediatric Exclusivity(PED) Sep 23, 2023
New Patient Population(NPP) Mar 23, 2023

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using CRISABOROLE ingredient

NCE-1 date: 23 September, 2022

Market Authorisation Date: 14 December, 2016

Treatment: Method of treating mild to moderate atopic dermatitis.

Dosage: OINTMENT;TOPICAL

How can I launch a generic of EUCRISA before it's drug patent expiration?
More Information on Dosage

EUCRISA family patents

Family Patents